These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 419965)

  • 1. Plasma medroxyprogesterone acetate levels following intramuscular or oral administration in patients with endometrial adenocarcinoma.
    Laatikainen T; Nieminen U; Adlercreutz H
    Acta Obstet Gynecol Scand; 1979; 58(1):95-9. PubMed ID: 419965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of medroxyprogesterone serum concentrations by the oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma.
    Sall S; DiSaia P; Morrow CP; Mortel R; Prem K; Thigpen T; Creasman W
    Am J Obstet Gynecol; 1979 Nov; 135(5):647-50. PubMed ID: 507117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration.
    Hiroi M; Stanczyk FZ; Goebelsmann U; Brenner PF; Lumkin ME; Mishell DR
    Steroids; 1975 Sep; 26(3):373-86. PubMed ID: 1198624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioimmunoassay for medroxyprogesterone acetate (Provera) using the 11alpha-hydroxy succinyl conjugate.
    Royer ME; Ko H; Campbell JA; Murray HC; Evans JS; Kaiser DG
    Steroids; 1974 May; 23(5):713-30. PubMed ID: 4365969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioimmunoassays of ethinyl-norgestrienone (R-2323) and medroxyprogesterone acetate (MPA) and their clinical applicability.
    Frick J; Bartsch G; Jakse G
    Urol Res; 1977; 5(2):55-9. PubMed ID: 69351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of breast cancer with medroxyprogesterone acetate.
    Muggia FM; Cassieth PA; Ochoa M; Flatow FA; Gellhorn A; Hyman GA
    Ann Intern Med; 1968 Feb; 68(2):328-37. PubMed ID: 4306126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioimmunoassay for serum medroxyprogesterone acetate in Thai women receiving injectable DMPA contraceptive.
    Werawatgoompa S; Pongpradit T; Leepipatpaiboon S; Sukanthanak A
    Contraception; 1979 Oct; 20(4):319-27. PubMed ID: 509958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of seizures with medroxyprogesterone acetate: preliminary report.
    Mattson RH; Cramer JA; Caldwell BV; Siconolfi BC
    Neurology; 1984 Sep; 34(9):1255-8. PubMed ID: 6540415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unsuccessful treatment of acromegaly with medroxyprogesterone acetate.
    Atkinson RL; Dimond RC; Howard WJ; Earll JM
    Acta Endocrinol (Copenh); 1974 Sep; 77(1):19-25. PubMed ID: 4408390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic study of different doses of Depo Provera.
    Fotherby K; Koetsawang S; Mathrubutham M
    Contraception; 1980 Nov; 22(5):527-36. PubMed ID: 6451351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment.
    Soufir JC; Jouannet P; Marson J; Soumah A
    Acta Endocrinol (Copenh); 1983 Apr; 102(4):625-32. PubMed ID: 6221496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medroxyprogesterone acetate (MPA) plasma levels after oral and intramuscular administration in a long-term study.
    Hesselius I; Johansson ED
    Acta Obstet Gynecol Scand Suppl; 1981; 101():65-70. PubMed ID: 6795891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progestogen treatment of recurrent endometrial carcinoma.
    Malkasian GD; Decker DG; Mussey E; Johnson CE
    Am J Obstet Gynecol; 1971 May; 110(1):15-23. PubMed ID: 5573604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum follicle-stimulating hormone, luteinizing hormone and progesterone concentrations in pseudopregnant rats treated with medroxyprogesterone acetate.
    de Greef WJ; Dullaart J; Zeilmaker GH
    J Endocrinol; 1976 Sep; 70(3):465-71. PubMed ID: 978105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endometrial histology and circulating levels of medroxyprogesterone acetate (MPA), estradiol, FSH and LH in women with MPA induced amenorrhoea compared with women with secondary amenorrhoea.
    Jeppsson S; Johansson ED; Ljungberg O; Sjöberg NO
    Acta Obstet Gynecol Scand; 1977; 56(1):43-8. PubMed ID: 842303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation.
    Cuna GR; Calciati A; Strada MR; Bumma C; Campio L
    Tumori; 1978 Apr; 64(2):143-9. PubMed ID: 354147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained effects on synthetic ovarian steroids of rat myometrial contractility.
    Parkington HC; Lipton A
    J Endocrinol; 1976 Aug; 70(2):223-7. PubMed ID: 965882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. After-effect of injection.
    Nelson M
    Vet Rec; 1977 Jan; 100(4):78. PubMed ID: 835219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA.
    Ortiz A; Hirol M; Stanczyk FZ; Goebelsmann U; Mishell DR
    J Clin Endocrinol Metab; 1977 Jan; 44(1):32-8. PubMed ID: 833262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.